Announcement | Jun 22, 2026Honigman Represents Nuwellis in $6.0 Million Public Offering

Honigman recently advised Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, in connection with its public offering of 1,903,338 shares of common stock and pre-funded warrants to purchase 18,096,662 shares of common stock, in each case with accompanying Series C warrants to purchase up to 60,000,000 shares of common stock and Series D warrants to purchase up to 20,000,000 shares of common stock, for gross proceeds of approximately $6.0 million.

The offering was priced at $0.30 per share of common stock and accompanying warrants and $0.2999 per pre-funded warrant and accompanying warrants. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable until exercised in full. The Series C and Series D warrants have an exercise price of $0.30 per share and will be exercisable for five years following stockholder approval and the effective date of a reverse stock split.

The Honigman team was led by Corporate Partners Phillip D. Torrence, Jessica M. Herron, Michael J. Rosenberg, and N. Danny Shulman, with support from Associates Daniel Altshuller and Sarah Meinel.